JURA Bio

JURA Bio is a private, pre-clinical stage biotech leveraging a proprietary, integrated AI and wet-lab platform to discover and develop novel therapeutics. The company's 'sovereign AI' approach uses its VISTA, LIFT, and LeaVS technologies to create a self-improving data generation and model training loop, enabling de novo design across antibodies, TCRs, peptides, and cell therapies. With strategic collaborations already announced, JURA is positioning itself at the frontier of AI-driven drug discovery by attempting to overcome the critical industry bottleneck of high-quality, functional training data.

Integrated AI/wet-lab platform featuring VISTA (AI-controlled DNA synthesis for 10^16-scale libraries), LIFT (AI-interpretable experiments for 100x data throughput), and LeaVS (co-designed inference for 100x learning acceleration). Creates a closed-loop, self-improving system for generating proprietary functional data and designing therapeutics.

JURA competes in the crowded AI drug discovery space against public companies like Recursion, Exscientia, and AbCellera, as well as private peers such as Generate Biomedicines and Evozyne. Its key differentiation is the closed-loop, sovereign data generation model, contrasting with competitors who often rely more heavily on public or partner data.